Yahoo13 Ağustos 2026 10:02 TR22 gün önce
CVRx Eyes Barostim Growth as Coverage Gains and BENEFIT-HF Trial Launches
CVRx (NASDAQ:CVRX) outlined its efforts to expand adoption of its Barostim therapy for heart failure patients, emphasizing sales-force execution, payer coverage progress and a large post-market clinical trial during Canaccord Genuity’s 46th Annual Growth Conference. President and CEO Kevin Hykes sa
Haberin Tamamı Kaynağında
Burada gördüğün özet, haber sağlayıcısından geliyor; metnin devamı yayıncının sitesinde — Yahoo
Haberde Geçen Şirketler
Benzer Haberler
The trading volume of these stocks is deviating from the norm in today's session.
ChartMill50 dakika önce
Sodexo : Monthly disclosure on share capital and voting rights August 31, 2026
Yahoo2 saat önce
ANF vs. TPR: Which Stock Is the Better Value Option?
Yahoo2 saat önce
Anthropic's IPO Push Just Got a $15 Billion Backstop
Yahoo2 saat önce
Why Is Circle Internet Group, Inc. (CRCL) Up 63.1% Since Last Earnings Report?
Yahoo2 saat önce